Table 2. Chemotherapy regimen used to treat Hodgkin's lymphoma according to age and risk group.
| Variables | Children, 0–12.9 yr (n = 74) | Adolescent, 13–18.9 yr (n = 99) | Young adult, 19–24.9 yr (n = 51) | P value | |
|---|---|---|---|---|---|
| Low | < 0.001 | ||||
| ABVD | 6 (18.8) | 17 (53.1) | 17 (100) | ||
| COPP | 14 (43.8) | 5 (15.6) | 0 (0) | ||
| ABVE-PC | 5 (15.6) | 2 (6.3) | 0 (0) | ||
| Other | 7 (21.9) | 8 (25.0) | 0 (0) | ||
| Intermediate | < 0.001 | ||||
| ABVD | 4 (17.4) | 20 (40.0) | 25 (89.3) | ||
| COPP | 9 (39.1) | 17 (34.0) | 1 (3.6) | ||
| ABVE-PC | 7 (30.4) | 7 (14.0) | 1 (3.6) | ||
| Other | 3 (13.0) | 6 (12.0) | 1 (3.6) | ||
| High | < 0.001 | ||||
| ABVD | 0 (0) | 7 (41.2) | 6 (100) | ||
| COPP | 13 (38.4) | 4 (23.5) | 0 (0) | ||
| ABVE-PC | 3 (15.8) | 5 (29.4) | 0 (0) | ||
| Other | 3 (15.8) | 1 (5.9) | 0 (0) | ||
Data are expressed as number (%).
ABVD = doxorubicin, bleomycin, vinblastine, dacarbazine, ABVE-PC = doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide, COPP = cyclophosphamide, vincristine, procarbazine, prednisone.